Five Under 5: Top Oncology Videos for the Week of 7/19

Welcome to The Five Under 5, your go-to roundup of the top 5 videos of the week.

These short videos are designed for busy oncologists to view on the go, and feature expert insights on the latest data, regulatory news, and clinical perspectives shaping oncology practice.

Here’s what you may have missed:

The Potential Significance of Daraxonrasib for PDAC Management: Shubham Pant, MD, MBBS

Shubham Pant, MD, MBBS, a professor in the Departments of Gastrointestinal Medical Oncology and Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center in Houston, discussed the potential of the RAS(ON) multiselective inhibitor daraxonrasib in pancreatic ductal adenocarcinoma. Reflecting on data from the phase 3 RASolute 302 trial (NCT06625320), Pant—who has treated patients with pancreatic cancer for more than 20 years—called the findings remarkable. He likened daraxonrasib to a molecular glue and described the RAS pathway as a light switch the agent helps turn off, outlining why the approach could meaningfully shift management of a historically difficult-to-treat disease.

The FDA Approval of Zidesamtinib in Pretreated ROS1+ NSCLC: Narjust Florez, MD

Narjust Florez, MD, associate medical director of the Cancer Care Access Program and a thoracic medical oncologist at Dana-Farber Cancer Institute in Boston, Massachusetts, discussed the July 22, 2026, FDA approval of zidesamtinib for adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer who received prior therapy. The approval was supported by the phase 1/2 ARROS-1 trial (NCT05118789). She framed the approval as an example of the fast pace of clinical oncology and a more tolerable option for this population, while noting an important unresolved question around how best to sequence therapies as the treatment landscape continues to evolve.

The Utility of Adjuvant Immunotherapy Alone in Early-Stage NSCLC: Amy L. Cummings, MD, PhD

Amy L. Cummings, MD, PhD, director of Inclusive Excellence at the Jonsson Comprehensive Cancer Center at UCLA in Los Angeles, California, addressed patient selection for adjuvant immunotherapy in resectable non–small cell lung cancer. She noted a growing trend toward using immunotherapy earlier in a patient’s course and, citing comments from Heather Wakelee, MD, of Stanford Medicine, reinforced that outcomes vary by patient. Cummings said this points to a need to better identify which patients stand to benefit from adjuvant immunotherapy alone.

Navigating Immunotherapy Cost and Value in Cancer Care: Amol Akhade, MD, MBBS

Amol Akhade, MD, MBBS, a medical oncologist at Fortis Hospitals, discussed how cost shapes immunotherapy decisions and what standard cost-effectiveness measures can miss for individual patients. He explained his preference for describing reduced-dose strategies as “optimal-dose” rather than “low-dose” immunotherapy, and highlighted the gap between population-level value metrics and the realities patients face when weighing treatment.

Systemic Therapy Advances in Muscle-Invasive Bladder Cancer: Matthew D. Galsky, MD

Matthew Galsky, MD, professor of medicine (hematology and medical oncology) and director of genitourinary medical oncology at the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai in New York, New York, traced the transformative systemic therapy advances in muscle-invasive bladder cancer over the past 3 decades. He identified cisplatin-based neoadjuvant chemotherapy as the first major breakthrough, noted the years of limited progress that followed, and described how the integration of enfortumab vedotin plus pembrolizumab into perioperative treatment—evaluated in the phase 3 KEYNOTE-B15/EV-304 trial (NCT04700124)—has ushered in a new era for the field.